Every 10-Q that ZEO SCIENTIFIX INC (ZEOX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZEOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZEOX filings page.
Zeo ScientifiX, Inc. reported sharply higher sales but remains unprofitable and faces substantial doubt about its ability to continue as a going concern. Revenue for the three months ended April 30, 2026 rose to $2.58 million from $1.15 million, driven mainly by allogenic biologic products in Florida’s evolving stem cell market. Six‑month revenue reached $4.03 million, with gross margins around 80%.
The company still posted a net loss of $145,000 for the quarter and $997,000 for the six months, though losses narrowed versus the prior year. Operating cash outflow was $609,000 over six months, offset by $1.95 million of equity financing and $376,000 from selling its Exotropin stake, lifting cash to $1.85 million. At April 30, 2026, stockholders’ equity improved to $712,000 and working capital to $155,000, yet management and auditors still highlight regulatory risk around FDA stem‑cell rules, reliance on new state laws such as Florida SB 1768, and the need for additional funding to support clinical trials and growth.
Zeo ScientifiX, Inc. reported strong top-line growth but continued losses and liquidity pressure for the quarter ended January 31, 2026. Revenue rose to $1.446M from $1.09M, a 32.7% increase driven by higher sales of allogenic aesthetic biologics and its PPX™ service platform. Gross profit improved to $1.165M, or 80.6% of revenue, while the net loss narrowed to $852,000 from $1.243M, or $0.12 per share. Operating cash flow was negative $471,000, and Zeo ended the quarter with $1.03M in cash, total assets of $2.571M, liabilities of $2.954M, and a stockholders’ deficit of $383,000. The company funded operations through $1.3M of private unit sales during the quarter and an additional $650,000 raised in February 2026. Management highlights growth opportunities from Florida’s new stem cell law (SB 1768) and an IRB-approved PPX™ musculoskeletal study, but reiterates substantial doubt about Zeo’s ability to continue as a going concern due to accumulated deficits, a working capital deficit of $879,000, dependence on external capital, and regulatory uncertainty around FDA biologics enforcement.
Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.
Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.